51760-23-7

Basic information

• Product Name: Benzene, 1-bromo-3,5-bis(bromomethyl)-
• Synonyms: Benzene, 1-bromo-3,5-bis(bromomethyl)-;5-BroMo-1,3-bis(broMoMethyl)benzene;1-Bromo-3,5-bis(bromomethyl)benzene;1,3-Bis(bromomethyl)-5-bromobenzene
• CAS NO: 51760-23-7
• Molecular Formula: C₈H₇Br₃
• Molecular Weight: 343
• EINECS: 939-347-6
• Mol File: 51760-23-7.mol
• Article Data: 5

Chemical Properties

• Melting Point: 97.5-99.0 °C
• Boiling Point: 343.0±32.0 °C(Predicted)
• Appearance: /
• Density: 2.082±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Benzene, 1-bromo-3,5-bis(bromomethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-bromo-3,5-bis(bromomethyl)-(51760-23-7)
• EPA Substance Registry System: Benzene, 1-bromo-3,5-bis(bromomethyl)-(51760-23-7)

Safety Data

• Hazardous Substances Data: 51760-23-7(Hazardous Substances Data)

Usage

General Description

Benzene, 1-bromo-3,5-bis(bromomethyl)- is a chemical compound with the molecular formula C8H6Br4. It is a derivative of benzene with two bromomethyl groups attached at the 1 and 3 positions. Benzene, 1-bromo-3,5-bis(bromomethyl)- is primarily used as an intermediate in organic synthesis, particularly in the production of pharmaceuticals and agrochemicals. It is also used as a building block in the manufacture of polymers and other industrial chemicals. Benzene, 1-bromo-3,5-bis(bromomethyl)- is considered to be hazardous due to its potential toxicity and environmental impact, and proper safety measures should be taken when handling and using this compound.

Upstream product

• 51760-21-5 dimethyl 5-bromoisophthalate 
• 23351-91-9 5-bromoisophthalic acid 
• 556-96-7 5-bromo-1,3-xylene 

Downstream Products

• 174575-03-2 diethyl <<3-bromo-5-(bromomethyl)phenyl>methyl>phosphonate 
• 179179-29-4 2,2'-(5-bromo-1,3-phenylene)bis(2-methylpropanenitrile) 
• 195209-24-6 1-bromo-3,5-bis(diethoxyphosphorylmethyl)benzene 
• 469890-01-5 tetramethyl [(5-bromo-1,3-phenylene)bis-(methylene)]bis-phosphonate 
• 572874-27-2 C₄₀H₂₅BrO₂ 
• 691884-18-1 1-bromo-3,5-bis(imidazole-1-ylmethyl)benzene 
• 108835-03-6 1-bromo-3,5-bis(chloromethyl)benzene 
• 869959-65-9 C₃₀H₂₉BrO₈ 
• 869959-64-8 C₂₈H₂₅BrO₈ 
• 869959-66-0 3',5'-bis-[2-(2,4-dimethoxy-6-methoxycarbonyl-phenyl)-vinyl]-biphenyl-4-carboxylic acid 

Relevant articles and documents

Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens

Pentamidine, an FDA-approved antiparasitic drug, was recently identified as an outer membrane disrupting synergist that potentiates erythromycin, rifampicin, and novobiocin against Gram-negative bacteria. The same study also described a preliminary structure-activity relationship using commercially available pentamidine analogues. We here report the design, synthesis, and evaluation of a broader panel of bis-amidines inspired by pentamidine. The present study both validates the previously observed synergistic activity reported for pentamidine, while further assessing the capacity for structurally similar bis-amidines to also potentiate Gram-positive specific antibiotics against Gram-negative pathogens. Among the bis-amidines prepared, a number of them were found to exhibit synergistic activity greater than pentamidine. These synergists were shown to effectively potentiate the activity of Gram-positive specific antibiotics against multiple Gram-negative pathogens such as Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Escherichia coli, including polymyxin- and carbapenem-resistant strains.

Structure-guided design of selective inhibitors of neuronal nitric oxide synthase

Nitric oxide synthases (NOSs) comprise three closely related isoforms that catalyze the oxidation of l-arginine to l-citrulline and the important second messenger nitric oxide (NO). Pharmacological selective inhibition of neuronal NOS (nNOS) has the potential to be therapeutically beneficial in various neurodegenerative diseases. Here, we present a structure-guided, selective nNOS inhibitor design based on the crystal structure of lead compound 1 in nNOS. The best inhibitor, 7, exhibited low nanomolar inhibitory potency and good isoform selectivities (nNOS over eNOS and iNOS are 472-fold and 239-fold, respectively). Consistent with the good selectivity, 7 binds to nNOS and eNOS with different binding modes. The distinctly different binding modes of 7, driven by the critical residue Asp597 in nNOS, offers compelling insight to explain its isozyme selectivity, which should guide future drug design programs.